Sutro Biopharma (STRO) EBIT Margin (2017 - 2025)
Sutro Biopharma recorded quarterly EBIT Margin of 576.5% in Q4 2025, down 15.31% quarter-over-quarter from 499.94% in Q3 2025, and down 13584.0% year-over-year from N/an in Q4 2024.
Sutro Biopharma's EBIT Margin history runs 9 years deep, the most recent figure standing at 576.5% for Q4 2025.
- In Q4 2025, EBIT Margin fell 13584.0% year-over-year to 576.5%; the TTM figure through Dec 2025 stood at 184.71% (up 25575.0% YoY), while the FY2025 annual figure was 154.53%, up 22981.0% from the prior year.
- EBIT Margin came in at 576.5% for Q4 2025 at Sutro Biopharma, down from 499.94% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 37.95% in Q4 2023 to a low of 1202.0% in Q1 2025.
- A 5-year average of 375.84% and a median of 370.19% in 2021 frame the typical range for EBIT Margin.
- Across the five-year window, EBIT Margin surged 60817 bps in 2023 and sank 76695 bps in 2025, its largest moves.
- Sutro Biopharma's EBIT Margin stood at 328.85% in 2021, then sank by 73 bps to 570.23% in 2022, then soared by 107 bps to 37.95% in 2023, then slumped by 1261 bps to 440.66% in 2024, then tumbled by 31 bps to 576.5% in 2025.
- According to Business Quant data, EBIT Margin over the past three periods registered 576.5%, 499.94%, and 5.25% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 17.83% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 23.02% |
| 10 | Sutro Biopharma | 242.87 Mn | 242.87 Mn | - | -576.50% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -576.50% |
| Sep 30, 2025 | -499.94% |
| Jun 30, 2025 | -5.25% |
| Mar 31, 2025 | -1,202.00% |
| Dec 31, 2024 | -440.66% |
| Sep 30, 2024 | -797.17% |
| Jun 30, 2024 | -273.51% |
| Mar 31, 2024 | -435.05% |
| Dec 31, 2023 | 37.95% |
| Sep 30, 2023 | -260.07% |
| Jun 30, 2023 | -443.52% |
| Mar 31, 2023 | -333.26% |
| Dec 31, 2022 | -570.23% |
| Sep 30, 2022 | -84.34% |
| Jun 30, 2022 | -68.97% |
| Mar 31, 2022 | -663.59% |
| Dec 31, 2021 | -328.85% |
| Sep 30, 2021 | -407.12% |
| Jun 30, 2021 | -34.96% |
| Mar 31, 2021 | -129.67% |
| Dec 31, 2020 | -300.11% |
| Sep 30, 2020 | -59.57% |
| Jun 30, 2020 | -173.38% |
| Mar 31, 2020 | -268.18% |
| Dec 31, 2019 | -130.76% |
| Sep 30, 2019 | -103.73% |
| Jun 30, 2019 | -130.02% |
| Mar 31, 2019 | -165.33% |
| Dec 31, 2018 | -17.16% |
| Sep 30, 2018 | -129.62% |
| Jun 30, 2018 | -211.92% |
| Mar 31, 2018 | -202.02% |
| Dec 31, 2017 | -375.45% |
| Sep 30, 2017 | -6.09% |